Correction to: Scientific Reports https://doi.org/10.1038/srep30980, published online 02 August 2016
This Article contains an error in Figure 6 where the bottom two images are vertical mirror images of each other.
The correct Figure 6 and accompanying legend appear below.
Nepenthes fluid protease treatment of gliadin prevents gliadin-induced inflammation in the NOD/DQ8 transgenic mouse model of gluten-sensitivity. Intraepithelial lymphocyte (IEL) counts quantitated by immunostaining of proximal small intestine villi tips, in sensitized mice challenged with pepsin-treated gliadin (positive control), vehicle alone (negative control, gliadin-free diet), fluid protease-treated gliadin (1:264 ratio) and recombinant nepenthesin-II treated gliadin (1:100 ratio). Representative immunostained sections of intestinal tissues shown to the right at 40× magnification. Statistical significance (n = 8 for each state, *p < 0.05, ***p < 0.001).
This change does not affect the conclusions of the Article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Rey, M., Yang, M., Lee, L. et al. Author Correction: Addressing proteolytic efficiency in enzymatic degradation therapy for celiac disease. Sci Rep 13, 956 (2023). https://doi.org/10.1038/s41598-023-28196-w
Published:
DOI: https://doi.org/10.1038/s41598-023-28196-w